|
You are subscribed to Oncology Drugs. This information has recently been updated, and is now available.
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
|
This email was sent to Esdek@podam.pl using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·
10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA |
 |
|
|
